IL17A and inflammatory bowel disease: As IL-23 antibodies inhibit solely the production of IL-17 from Th17 cells, other cellular sources of IL-17 remain unaffected, therefore highlighting their beneficial role in the treatment of concomitant psoriasis and IBD [159].